CAP2 had an AUROC of 0.84, sensitivity of 82.9%, and specificity of 79.6% for the detection of ANHC (n = 35), and for the detection of AFP-negative early HCC, CAP2 also presented a good performance (AUROC 0.80, sensitivity 80.0%, and specificity 79.6% (99). This evidence concerns the gene AFP and hepatocellular carcinoma.